Thyrocare Technologies Limited
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
What Thyrocare files
- Others82
- Investor Meet26
- Important23
- Updates18
- Insider Trade13
- Board Meeting10
API Holdings repaid INR 1,700 Cr NCDs, releasing the pledge on 60.92% of Thyrocare's equity shares held by Docon. This frees up the parent's shareholding, with no direct impact on Thyrocare's operations.
Thyrocare's board approved evaluating a potential demerger of its wholly-owned subsidiary Nueclear Healthcare's radiology business. This move aims to separate the advanced cancer diagnostics and nuclear medicine unit, currently at an initial evaluation stage.
Thyrocare reported strong Q1FY27 results: Revenue surged 24% YoY to ₹240.02 Cr, EBITDA 34% to ₹77.27 Cr, and PAT 34% to ₹51.33 Cr. It processed 55.2 million tests, up 28%. The company also expanded into Specialty Diagnostics.
Thyrocare has announced its 26th AGM on June 30, 2026. Investors should note the Final Dividend Record Date of June 23, 2026, with payment by July 29, 2026. The Annual Report for FY25-26 is now accessible online for shareholders.
Thyrocare reported strong FY26 consolidated results: revenue hit 829.04 Cr, profit soared to 163.05 Cr (EPS Rs. 10.27). Exceptional items of 6.16 Cr included new labor code impact. The Board proposed a Rs. 7/share dividend.